|
Market Closed -
Euronext Paris
18:55:00 21/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.340 EUR | +6.36% |
|
-4.10% | -22.00% |
| 08-10 | ABL Diagnostics Plans Listing Transfer to Euronext Growth Paris | MT |
| 07-23 | French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell | MT |
Company Valuation: ABL Diagnostics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2.96 | 3.988 | 29 | 156.3 | 39.64 | 48.34 |
| Change | - | 34.75% | 627.14% | 439.03% | -74.64% | 21.95% |
| Enterprise Value (EV) 1 | 0.6006 | 1.286 | 30.64 | 157.5 | 41.66 | 49.27 |
| Change | - | 114.05% | 2,283.25% | 414.19% | -73.55% | 18.27% |
| P/E | -33.1x | 15.5x | 206x | 2,876x | 123x | 50x |
| PBR | 1.25x | 1.52x | 34.5x | 23.1x | 5.29x | 6.32x |
| PEG | - | -0x | -4.5x | -30.2x | 0x | 0x |
| Capitalization / Revenue | - | 221,548,833,333x | 3,097,618x | 25,256,446x | 6,753,666x | 6,068,760x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -6.59x | -12.5x | 517x | -240x | -85x | 155x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | 0.05 | 0.11 |
| Rate of return | - | - | - | - | 2.03% | 3.67% |
| EPS 2 | -0.0445 | 0.1285 | 0.07 | 0.003373 | 0.02 | 0.06 |
| Distribution rate | - | - | - | - | 250% | 183% |
| Net sales | - | 0.000018 | 9.361 | 6.189 | 5.869 | 7.966 |
| EBITDA | - | - | 0.62 | 0.005134 | 0.2459 | 0.4283 |
| EBIT 1 | -0.0912 | -0.1026 | 0.0593 | -0.6571 | -0.4904 | 0.3171 |
| Net income 1 | -0.0893 | 0.2579 | 1.106 | 0.0544 | 0.2852 | 0.9867 |
| Net Debt 1 | -2.359 | -2.702 | 1.643 | 1.244 | 2.024 | 0.9326 |
| Reference price 2 | 1.475 | 1.988 | 14.452 | 9.700 | 2.460 | 3.000 |
| Nbr of stocks (in thousands) | 2,006 | 2,006 | 2,006 | 16,114 | 16,114 | 16,114 |
| Announcement Date | 4/23/21 A | 5/20/22 A | 8/1/23 A | 7/31/24 A | 5/6/25 A | 5/7/26 A |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 43.9M | |
| 33.46x | 4.49x | 17.25x | 2.2% | 202B | |
| 21.15x | 3.63x | 12.76x | 3.19% | 119B | |
| 17.42x | 0.2x | 12.74x | 0.75% | 60.69B | |
| 30.37x | 7.55x | 19.28x | 1.31% | 52.38B | |
| 37x | 3.53x | 12.12x | 2.04% | 52.3B | |
| 37.01x | 6.52x | 20.46x | -.--% | 34.85B | |
| 44.97x | 1.28x | 11.71x | 0.17% | 30.06B | |
| 41.17x | 7.21x | 25.89x | 0.26% | 24.85B | |
| 19.84x | 3.06x | 11.16x | 1.45% | 23.84B | |
| Average | 31.38x | 4.16x | 15.93x | 1.26% | 60.03B | |
| Weighted average by Cap. | 29.99x | 4.08x | 15.65x | 1.82% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ABLD Stock
- Valuation ABL Diagnostics
Select your edition
All financial news and data tailored to specific country editions
